Overview |
bs-70722r-100ul |
VEGFR-3 (N-terminus) Antibody |
WB |
The antibody detects a 170 kDa* band corresponding to VEGFR-3 in western blots of human endothelial and K-562 cells, and shows strong reactivity to recombinant human VEGFR-3, but not VEGFR-1 or VEGFR-2. This sequence has two amino acid differences from rat VEGFR-3, and five amino acid differences from mouse VEGFR-3. |
Human, Rat |
Specifications |
Unconjugated |
Rabbit |
A synthetic peptide (coupled to carrier protein) corresponding to amino acids from the N-terminal region of human VEGFR-3. |
Polyclonal |
IgG |
Antigen Affinity purification |
PBS + 1 mg/ml BSA, 0.05% NaN3 and 50% glycerol |
Storage at -20°C is recommended, as aliquots may be taken without freeze/thawing due to presence of 50% glycerol. Stable for at least 1 year at -20°C. |
Target |
P35916 |
FLT-4, Vascular endothelial growth factor receptor 3 |
Vascular endothelial growth factor receptor-2 (VEGFR-2/Flk-1/KDR) is the primary receptor for VEGF in endothelial cells. Other VEGFR family members, VEGFR-1 (Flt-1) and VEGFR-3 (Flt-4), can also transduce the intracellular signals of VEGF. However, the role of VEGFR-1 is observed mainly during embryonic angiogenesis and VEGFR-3 signaling may be restricted to specific types of endothelial cells. Major autophosphorylation sites of VEGFR-2 are located in the kinase insert domain (Tyr-951/996) and in the tyrosine kinase catalytic domain (Tyr-1054/1059). Other sites, Tyr-1175 and Tyr-1212 provide docking sites for downstream signaling molecules. Activation of VEGFR-2 also phosphorylates Tyr-801, leading to PI3-kinase-Akt activation and increases in endothelial nitric oxide synthase activity. Phosphorylation of mutliple sites in VEGFR-2 is required for downstream activation of several signaling pathways that control proliferation, chemotaxis, and sprouting during angiogenesis. |
Application Dilution |
WB |
1:300-5000 |